{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/complexity-paradox-why-better-science-delaying-oncology-trials#webpage",
"url": "https://www.fortrea.com/insights/complexity-paradox-why-better-science-delaying-oncology-trials",
"name": "The complexity paradox: Why better science is delaying oncology trials",
"description": "This Fortrea article examines the growing complexity paradox in oncology clinical development, where advances in precision medicine, biomarker-driven research, and increasingly sophisticated scientific approaches are creating new challenges for clinical trial execution. As oncology drug development becomes more targeted and personalized, sponsors face greater complexity in patient identification, biomarker strategy, protocol design, site selection, operational execution, and trial management. While these scientific advances have improved the ability to develop therapies for specific patient populations, they have also contributed to longer timelines, increased study complexity, and greater operational demands across clinical development programs. The article explores how modern oncology trials must balance scientific innovation with practical execution, highlighting the need for efficient study design, operational agility, strategic planning, and integrated delivery models that can support increasingly complex precision oncology programs while maintaining development speed and execution quality."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "The complexity paradox: Why better science is delaying oncology trials",
"item": "https://www.fortrea.com/insights/complexity-paradox-why-better-science-delaying-oncology-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/complexity-paradox-why-better-science-delaying-oncology-trials#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/complexity-paradox-why-better-science-delaying-oncology-trials#webpage"
},
"headline": "Why Precision Oncology Increases Oncology Clinical Trial Complexity | Fortrea Article",
"description": "This Fortrea article examines the growing complexity paradox in oncology clinical development, where advances in precision medicine, biomarker-driven research, and increasingly sophisticated scientific approaches are creating new challenges for clinical trial execution. As oncology drug development becomes more targeted and personalized, sponsors face greater complexity in patient identification, biomarker strategy, protocol design, site selection, operational execution, and trial management. While these scientific advances have improved the ability to develop therapies for specific patient populations, they have also contributed to longer timelines, increased study complexity, and greater operational demands across clinical development programs. The article explores how modern oncology trials must balance scientific innovation with practical execution, highlighting the need for efficient study design, operational agility, strategic planning, and integrated delivery models that can support increasingly complex precision oncology programs while maintaining development speed and execution quality.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-12",
"dateModified": "2026-05-12",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/why-better-science-is-delaying-oncology-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}